NYPOZI txid

Generic name: filgrastim-txid

Used for: Lowering the risk of infection during chemotherapy · Faster white blood cell recovery in leukemia (AML) treatment · Faster white blood cell recovery after a bone marrow transplant · Collecting your own stem cells from the blood · Low white blood cells from birth, cyclic or unexplained · Radiation sickness (acute radiation syndrome) · 5 more

How do you pay?

How to pay the least

Ask for the cash price

NYPOZI txid

NYPOZI txid is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for NYPOZI txid’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameNYPOZI txid
Authorized genericfilgrastim-txid
Regular genericfilgrastim-txid
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as NYPOZI txid?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from NYPOZI txid’s maker. Ask the pharmacy for NYPOZI txid’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is NYPOZI txid itself, from the same company, sold without the brand name, and usually for less. For now NYPOZI txid is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

NYPOZI txid is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for NYPOZI txid’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

NYPOZI is a leukocyte growth factor indicated to:

  • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
  • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
  • Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
  • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
  • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Source: the FDA label for NYPOZI txid (Tanvex BioPharma USA, Inc.), January 15, 2026. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/nypozi-txid/